Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2002

View Archived Issues

Ortho-McNeil submits sNDA for Levaquin for nosocomial pneumonia

IND submitted for AGI-1096 in prevention of organ transplant rejection

Abgenix initiates phase II trial of ABX-EGF in prostate cancer

IND approval for NicOx's HCT-1026 for urinary incontinence

Antitrust clearance obtained for MedImmune's acquisition of Aviron

ISTA files initial section of Vitrase NDA

Antisoma and Abbott revise pemtumomab licensing agreement

CancerVax files IND application to conduct pivotal trials of Canvaxin in advanced colon cancer

Nucleotide inhibitors of HBV replication under development at Origenix

Early clinical data indicate safety and efficacy of ISS-1018 coadministered with HBsAg

In vitro profile of PNU-177553, a new oxazolidinone, described at ICAAC meeting

15-Methylketolide derivatives of erythromycin A designed by R.W. Johnson and Kosan

GSK will market Natrecor in Europe under new agreement with Scios

Lead A2A antagonist selected by Vernalis for further development as potential PD therapy

LY-570310, a new oral hepatitis C protease inhibitor, designated a development candidate

Bacterial FabI inhibitors as novel antibiotics; GSK discusses findings at ICAAC

Phase IIa results of ABX-IL-8 in rheumatoid arthritis do not warrant progression to phase IIb trials

Contraceptive gel enters clinical trials

NB-1011 enters phase I/II trial in colon cancer

FDA approves IND for Albuleukin to enter clinical trials in treatment of cancer

Versicor initiates phase III trial for anidulafungin in invasive aspergillosis

Inhibitors of sCD23 formation and TNF processing patented by GSK

Oxadiazole MMP inhibitors reported useful for renal diseases in Shionogi patent

GSK-3beta inhibitors and their use described in recent patent

Dual 5-HT1A autoreceptor antagonists and 5-HT uptake inhibitors designed by AHP

New somatostatin receptor agonists selective for sst2 subtype and potential uses thereof

MMP-2 inhibitors identified at Shionogi as anticancer agents

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026